{"filing":{"accession_number":"0001213900-26-073813","cik":"0001023549","ticker":"XTLB","company_name":"XTL BIOPHARMACEUTICALS LTD","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ea0296604-6k_xtlbio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1023549/000121390026073813/ea0296604-6k_xtlbio.htm"},"events":[{"id":15111,"run_id":13477,"accession_number":"0001213900-26-073813","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The press release announces the completion of XTL's acquisition of Psyga Bio Ltd., with XTL acquiring 269,095 shares representing approximately 83.40% of Psyga's issued and outstanding share capital on a fully diluted basis. The transaction involves stock-based consideration (issuance of ADSs representing 33.36% of XTL's post-issuance capital) plus success-based milestone payments (up to 25.02% additional capital). This is a material acquisition that fundamentally transforms XTL into a dedicated psychedelic medicine company with clinical-stage assets, manufacturing infrastructure, and IP portfolio.","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12752,"accession_number":"0001213900-26-073813","item_number":"EX-99.1","item_title":"ea029660401ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The press release announces the completion of XTL's acquisition of Psyga Bio Ltd., with XTL acquiring 269,095 shares representing approximately 83.40% of Psyga's issued and outstanding share capital on a fully diluted basis. The transaction involves stock-based consideration (issuance of ADSs representing 33.36% of XTL's post-issuance capital) plus success-based milestone payments (up to 25.02% additional capital). This is a material acquisition that fundamentally transforms XTL into a dedicated psychedelic medicine company with clinical-stage assets, manufacturing infrastructure, and IP portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:26:51.668852+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12752,"accession_number":"0001213900-26-073813","item_number":"EX-99.1","item_title":"ea029660401ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The press release announces the completion of XTL's acquisition of Psyga Bio Ltd., with XTL acquiring 269,095 shares representing approximately 83.40% of Psyga's issued and outstanding share capital on a fully diluted basis. The transaction involves stock-based consideration (issuance of ADSs representing 33.36% of XTL's post-issuance capital) plus success-based milestone payments (up to 25.02% additional capital). This is a material acquisition that fundamentally transforms XTL into a dedicated psychedelic medicine company with clinical-stage assets, manufacturing infrastructure, and IP portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:26:51.668852+00:00","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-06-30"}]}